Company profile ALRN

Aileron Therapeutics Inc
aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of t...he genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig Show More
Quarter analysis & expected interestLast update: February 08 2024 14:27:57.

After 39 days of this quarter the interest is at 30.0. Based on that we can calculate that during remaining 52 days it will total up to 70.0.
Aileron Therapeutics expected interest is significantly lower compared to previous quarter (-61.7%) but similar to same quarter last year.

YearQ1Q2Q3Q4
2019155
72
-53.5% QoQ
147
104.2% QoQ
129
-12.2% QoQ
2020 127
-18.1% YoY -1.6% QoQ
224
211.1% YoY 76.4% QoQ
210
42.9% YoY -6.2% QoQ
306
137.2% YoY 45.7% QoQ
2021 392
208.7% YoY 28.1% QoQ
98
-56.2% YoY -75.0% QoQ
142
-32.4% YoY 44.9% QoQ
132
-56.9% YoY -7.0% QoQ
2022 128
-67.3% YoY -3.0% QoQ
96
-2.0% YoY -25.0% QoQ
114
-19.7% YoY 18.8% QoQ
55
-58.3% YoY -51.8% QoQ
2023 102
-20.3% YoY 85.5% QoQ
113
17.7% YoY 10.8% QoQ
103
-9.6% YoY -8.8% QoQ
183
232.7% YoY 77.7% QoQ
2024 30
-70.6% YoY -83.6% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Aileron Therapeutics search interestLast update: February 08 2024 14:27:56.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 14:27:59.

The average 5 years interest of Aileron Therapeutics was 11.72 per week.
The last year interest of Aileron Therapeutics compared to the last 5 years has changed by -12.88%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -6.5%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 14:28:03.

After 39 days of this quarter the interest is at 41.0. Based on that we can calculate that during remaining 52 days it will total up to 96.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
20190
162
inf% QoQ
206
27.2% QoQ
179
-13.1% QoQ
2020 167
inf% YoY -6.7% QoQ
94
-42.0% YoY -43.7% QoQ
54
-73.8% YoY -42.6% QoQ
169
-5.6% YoY 213.0% QoQ
2021 67
-59.9% YoY -60.4% QoQ
192
104.3% YoY 186.6% QoQ
0
-100.0% YoY -100.0% QoQ
215
27.2% YoY inf% QoQ
2022 22
-67.2% YoY -89.8% QoQ
179
-6.8% YoY 713.6% QoQ
115
inf% YoY -35.8% QoQ
349
62.3% YoY 203.5% QoQ
2023 114
418.2% YoY -67.3% QoQ
115
-35.8% YoY 0.9% QoQ
58
-49.6% YoY -49.6% QoQ
131
-62.5% YoY 125.9% QoQ
2024 41
-64.0% YoY -68.7% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and ALRN-6924 search interestLast update: February 08 2024 14:28:03.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 14:28:04.

The average 5 years interest of ALRN-6924 was 10.07 per week.
The last year interest of ALRN-6924 compared to the last 5 years has changed by -20.95%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -24.33%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Solid tumor treatments to provide analysis

Correlation between past revenue and Solid tumor treatments search interest

There is not enough data for Solid tumor treatments to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Solid tumor treatments to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 14:28:10.

After 39 days of this quarter the interest is at 210.0. Based on that we can calculate that during remaining 52 days it will total up to 490.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019183
383
109.3% QoQ
293
-23.5% QoQ
339
15.7% QoQ
2020 273
49.2% YoY -19.5% QoQ
276
-27.9% YoY 1.1% QoQ
313
6.8% YoY 13.4% QoQ
298
-12.1% YoY -4.8% QoQ
2021 303
11.0% YoY 1.7% QoQ
285
3.3% YoY -5.9% QoQ
310
-1.0% YoY 8.8% QoQ
403
35.2% YoY 30.0% QoQ
2022 526
73.6% YoY 30.5% QoQ
323
13.3% YoY -38.6% QoQ
276
-11.0% YoY -14.6% QoQ
279
-30.8% YoY 1.1% QoQ
2023 431
-18.1% YoY 54.5% QoQ
305
-5.6% YoY -29.2% QoQ
379
37.3% YoY 24.3% QoQ
364
30.5% YoY -4.0% QoQ
2024 210
-51.3% YoY -42.3% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Lymphoma treatments search interestLast update: February 08 2024 14:28:09.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 14:28:10.

The average 5 years interest of Lymphoma treatments was 25.87 per week.
The last year interest of Lymphoma treatments compared to the last 5 years has changed by 9.78%.
The interest for Lymphoma treatments is seasonal.
The last year interest is comparable to 5 years ago. It has changed only by 13.24%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 14:28:15.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
AML treatments expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
201914
40
185.7% QoQ
40
0.0% QoQ
57
42.5% QoQ
2020 130
828.6% YoY 128.1% QoQ
46
15.0% YoY -64.6% QoQ
98
145.0% YoY 113.0% QoQ
190
233.3% YoY 93.9% QoQ
2021 48
-63.1% YoY -74.7% QoQ
56
21.7% YoY 16.7% QoQ
47
-52.0% YoY -16.1% QoQ
64
-66.3% YoY 36.2% QoQ
2022 97
102.1% YoY 51.6% QoQ
97
73.2% YoY 0.0% QoQ
90
91.5% YoY -7.2% QoQ
72
12.5% YoY -20.0% QoQ
2023 104
7.2% YoY 44.4% QoQ
79
-18.6% YoY -24.0% QoQ
96
6.7% YoY 21.5% QoQ
43
-40.3% YoY -55.2% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and AML treatments search interestLast update: February 08 2024 14:28:14.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 14:28:16.

The average 5 years interest of AML treatments was 5.78 per week.
The last year interest of AML treatments compared to the last 5 years has changed by -3.46%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 38.12%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for MDS treatments to provide analysis

Correlation between past revenue and MDS treatments search interest

There is not enough data for MDS treatments to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for MDS treatments to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 14:28:21.

After 39 days of this quarter the interest is at 108.0. Based on that we can calculate that during remaining 52 days it will total up to 252.0.
Small cell lung cancer treatments expected interest is significantly higher compared to previous quarter (+687.5%) and same quarter last year (+1160.0%).

YearQ1Q2Q3Q4
201919
20
5.3% QoQ
25
25.0% QoQ
15
-40.0% QoQ
2020 21
10.5% YoY 40.0% QoQ
11
-45.0% YoY -47.6% QoQ
25
0.0% YoY 127.3% QoQ
23
53.3% YoY -8.0% QoQ
2021 19
-9.5% YoY -17.4% QoQ
23
109.1% YoY 21.1% QoQ
13
-48.0% YoY -43.5% QoQ
8
-65.2% YoY -38.5% QoQ
2022 5
-73.7% YoY -37.5% QoQ
12
-47.8% YoY 140.0% QoQ
34
161.5% YoY 183.3% QoQ
24
200.0% YoY -29.4% QoQ
2023 20
300.0% YoY -16.7% QoQ
3
-75.0% YoY -85.0% QoQ
34
0.0% YoY 1033.3% QoQ
32
33.3% YoY -5.9% QoQ
2024 108
440.0% YoY 237.5% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Small cell lung cancer treatments search interestLast update: February 08 2024 14:28:21.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 14:28:22.

The average 5 years interest of Small cell lung cancer treatments was 1.89 per week.
The last year interest of Small cell lung cancer treatments compared to the last 5 years has changed by 86.24%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 113.33%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aileron Therapeutics trials to provide analysis

Correlation between past revenue and Aileron Therapeutics trials search interest

There is not enough data for Aileron Therapeutics trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aileron Therapeutics trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 14:28:29.

After 39 days of this quarter the interest is at 31.0. Based on that we can calculate that during remaining 52 days it will total up to 72.0.
Renegade Therapeutics expected interest is significantly lower compared to previous quarter (-59.1%) but similar to same quarter last year.

YearQ1Q2Q3Q4
201943
144
234.9% QoQ
59
-59.0% QoQ
16
-72.9% QoQ
2020 32
-25.6% YoY 100.0% QoQ
80
-44.4% YoY 150.0% QoQ
75
27.1% YoY -6.2% QoQ
21
31.2% YoY -72.0% QoQ
2021 106
231.2% YoY 404.8% QoQ
46
-42.5% YoY -56.6% QoQ
16
-78.7% YoY -65.2% QoQ
33
57.1% YoY 106.2% QoQ
2022 31
-70.8% YoY -6.1% QoQ
123
167.4% YoY 296.8% QoQ
83
418.8% YoY -32.5% QoQ
86
160.6% YoY 3.6% QoQ
2023 62
100.0% YoY -27.9% QoQ
153
24.4% YoY 146.8% QoQ
213
156.6% YoY 39.2% QoQ
176
104.7% YoY -17.4% QoQ
2024 31
-50.0% YoY -82.4% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Renegade Therapeutics search interestLast update: February 08 2024 14:28:29.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 14:28:29.

The average 5 years interest of Renegade Therapeutics was 6.24 per week.
The last year interest of Renegade Therapeutics compared to the last 5 years has changed by 83.01%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 102.12%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Aileron Therapeutics -stock -company to provide analysis

Correlation between past revenue and Aileron Therapeutics -stock -company search interest

There is not enough data for Aileron Therapeutics -stock -company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Aileron Therapeutics -stock -company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ALRN
Earnings date: 2024-03-20 After close
Company name: Aileron Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2025-01-10T11:30:00-05:00

PR Newswire
Aileron Therapeutics Announces Rebranding to Rein Therapeutics

2024-11-14T16:15:00-05:00

PR Newswire
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

2024-11-14T16:08:01-05:00

SEC
8-K Form - Current report, items 2.02 and 9.01 - Aileron Therapeutics, Inc. (0001420565) (Filer)

2024-11-14T16:03:30-05:00

SEC
10-Q Form - Quarterly report [Sections 13 or 15(d)] - Aileron Therapeutics, Inc. (0001420565) (Filer)

2024-11-13T07:00:00-05:00

PR Newswire
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

2024-11-05T17:17:59-05:00

SEC
SCHEDULE 13G/A Form - [Amend] Statement of Beneficial Ownership by Certain Investors - Aileron Therapeutics, Inc. (0001420565) (Subject)

2024-10-31T07:30:00-04:00

PR Newswire
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma

2024-10-12T09:00:00-04:00

PR Newswire
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis

2024-09-23T07:30:00-04:00

PR Newswire
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

2024-08-22T16:09:02-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Aileron Therapeutics, Inc. (0001420565) (Issuer)

2024-08-22T16:07:24-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Aileron Therapeutics, Inc. (0001420565) (Issuer)

2024-08-22T16:06:55-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Aileron Therapeutics, Inc. (0001420565) (Issuer)

2024-08-22T16:06:16-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Aileron Therapeutics, Inc. (0001420565) (Issuer)

2024-08-22T16:05:58-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - Aileron Therapeutics, Inc. (0001420565) (Issuer)

2024-08-21T16:17:00-04:00

SEC
8-K Form - Current report, items 5.07 and 9.01 - Aileron Therapeutics, Inc. (0001420565) (Filer)